Jeffrey Potts, MD
Internal Medicine · Bay City, MINPI 1700804820
Payments from drug & device makers
Across 337 payments — averaging $43,549 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$13.9M
- Pfizer$492K
- Regeneron$230K
- Averitas Pharma Inc.$20K
- Eli Lilly Export S.A. Puerto Rico Branch$2K
- EMD Serono, Inc.$2K
- plus $1K from 26 others
Across 13 payments — averaging $9097.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$117K
- Eli Lilly Export S.A. Puerto Rico Branch$790
What the payments were for
- Speaking & faculty fees$767%
- Food & beverage$96392%
- Education$71%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 134 | $13,930,151 |
| Pfizer | 46 | $491,930 |
| Regeneron | 82 | $229,831 |
| Averitas Pharma Inc. | 17 | $19,513 |
| Eli Lilly Export S.A. Puerto Rico Branch | 2 | $2,056 |
| EMD Serono, Inc. | 2 | $1,647 |
| Novo Nordisk | 8 | $141 |
| Lilly USA, LLC | 10 | $104 |
| GSK | 5 | $91 |
| Redhill Biopharma Inc. | 1 | $76 |
| Novartis | 3 | $71 |
| Astellas Pharma US Inc | 3 | $68 |
| AstraZeneca | 2 | $40 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Amgen | 2 | $36 |
| Organon | 2 | $33 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Boston Scientific | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Seqirus USA Inc | 1 | $22 |
| Eisai Inc. | 1 | $22 |
| Dexcom, Inc. | 1 | $22 |
| Genentech USA, Inc. | 1 | $21 |
| Bayer | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $19 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $18 |
| Hologic Sales And Service, LLC | 1 | $16 |
| AbbVie | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Abbott | 1 | $15 |
| Exact Sciences | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
How this compares
$14,676,134 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 239 | $265,457 |
| OzempicSemaglutide | 132 | $179,958 |
| JardianceEmpagliflozin | 111 | $164,259 |
| MounjaroTirzepatide | 97 | $121,566 |
| XareltoRivaroxaban | 68 | $93,313 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 272 | $86,832 |
| TrulicityDulaglutide | 40 | $65,246 |
| FarxigaDapagliflozin Propanediol | 51 | $64,839 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $54,185 |
| JanuviaSitagliptin Phosphate | 31 | $38,203 |
| EntrestoSacubitril/Valsartan | 24 | $36,096 |
| Tresiba Flextouch U-100Insulin Degludec | 31 | $29,872 |
| MyrbetriqMirabegron | 27 | $28,078 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 34 | $19,678 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 97 | $18,960 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo, Paxlovid | $491,930 | $364,378550 claims |
| Lilly USA, LLCMounjaro, Trulicity | $104 | $186,812137 claims |
| Novo NordiskOzempic | $141 | $179,958132 claims |
| AstraZenecaFarxiga, Brilinta | $40 | $77,76168 claims |
| GSKTrelegy Ellipta, Shingrix | $91 | $69,361115 claims |
| NovartisEntresto | $71 | $36,09624 claims |
| Astellas Pharma US IncMyrbetriq | $68 | $28,07827 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Bay City
- Ulka VaishampayanAnn Arbor$33.7M
- Neil FraserTroy$14.3M
- Abdulhassan SaadDearborn$11.5M
- Leslie PelkeyGrand Rapids$8.5M
- Jay SandbergTroy$8.3M
- Ding WangDetroit$6.8M
- Dipenkumar ModiDetroit$4.1M
- Ahmed ArifFlint$4.1M
- Sudipto MukherjeeRoyal Oak$3.1M
- Steven KatzmanLivonia$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.